Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination.

A Prospective, Multi-center Trial of NovoTTF-100A Together With Temozolomide Compared to Temozolomide Alone in Patients with Newly Diagnosed GBM

You are here

Since standard treatment (Surgery followed by Radiation therapy with adjuvant Temozolomide and then maintenance Temozolomide alone) in subjects diagnosed with glioblastoma multiforme (GBM) is of limited efficacy, this randomized controlled clinical trial sets to compare treatment using a new experimental device, the NovoTTF-100A together with maintenance Temozolomide, to maintenance Temozolomide alone (following surgery and radiation therapy with adjuvant Temozolomide).  NovoCure has shown that when properly tuned, very low intensity, intermediate frequency electric fields (TTFields) stunt the growth of tumor cells.


This study is closed to new enrollment


Contact: Susan Pannullo, M.D.